The National Institute for Health and Care Excellence (NICE) has approved Vertex Pharmaceuticals’ Casgevy (exagamglogene ...

Vertex Pharmaceuticals (NASDAQ:VRTX) announced Friday a reimbursement agreement with England’s National Health Service (NHS) ...

Vertex Pharma's £1.65 million ($2.05 million) gene-editing therapy for sickle cell disease (SCD), Casgevy, has been given the ...

People in England to benefit from groundbreaking one-off gene therapy for severe sickle cell disease approved by NICE ...

People in England with sickle cell will be able to get the world’s first CRISPR-based medicine under an agreement between the ...

Around 1,700 people could be eligible for the one-time treatment, which is seen as a less risky alternative to a donor stem ...

Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) shares are trading higher Friday following two major developments that strengthen ...

Vertex Pharmaceuticals Inc. (VRTX), a commercial-stage global biotechnology company, announced Friday a reimbursement agreement with ...

Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy ...

It is believed around 1,700 people could be eligible for the treatment, while the NHS estimates around 50 people a year will ...

Vertex Pharmaceuticals (NASDAQ ... to allow patients with sickle cell disease (SCD) to access its gene-edited therapy Casgevy, developed with CRISPR Therapeutics (NASDAQ:CRSP).